期刊文献+

盐酸伐昔洛韦片的人体相对生物利用度及生物等效性 被引量:2

The relative bioavailability and bioequivalence of valaciclovir hydrochloride tablets in healthy volunteers
下载PDF
导出
摘要 目的:研究盐酸伐昔洛韦片的人体相对生物利用度和生物等效性。方法:健康志愿者20名,随机双交叉单剂量口服2种制剂的盐酸伐昔洛韦片,剂量分别为0.3g,剂间间隔为1周。分别于服药后14h内多点抽取静脉血;用高效液相色谱(HPLC)法测定血浆中阿昔洛韦的浓度。用DAS软件计算人体相对生物利用度并评价两种制剂生物等效性。结果:单剂量口服盐酸伐昔洛韦试验制剂和参比制剂后血浆阿昔洛韦的Gmax分别为(2.75±0.68)μg/ml和(2.68±0.82)μg/ml;tmax分别为(1.44±0.67)h和(1.46±0.77)h;AUC(0~14)分别为(9.53±2.00)μg/(h·ml)和(9.58±1.87)μg/(h·ml);AUG0~inf)分别为(9.94±2.22)μg/(h·ml)和(10.12±1.92)μg/(h·ml)。AuC(0~14)的90%可信区间为94.1%~104.3%,AUC(0~inf)的90%可信区间为93.0%~102.8%,Cmax的90%可信区间为95.7%~113.9%。结论:试验制剂与参比制剂的人体相对生物利用度为(100.4±17.0)%,2种制剂具有生物等效性。 Objective:To study the relative bioavailability and bioequivalence of valaciclovir hydrochloride tablets in healthy volunteers. Methods : A single oral dose of 0.3 g valaciclovir hydrochloride test and reference formulations were given to 20 healthy volunteers according to a randomized crossover design with an alternative interval in one week. Venous blood sampling was conducted consequently within 14 hours for detecting plasma acyclovir concentration with high performance liquid chromatography (HPLC). The pharmacokinetics parameter was calculated completely and the bioavailability and bioequivalence of two formulations were evaluated by DAS program. Results : After a single dose of acyclovir hydrochloride of test and reference formulations, the pharmacokinetics parameters for acyclovir were as follows: Cmax was(2. 75 ± 0.68)μg/ml and (2.68 ± 0.82)μg/ml; tmax was (1.44±0.67)h and (1.46 ± 0.77)h; AUC(0-14) was (9.53 ± 2.00) μg/(h· ml) and (9.58± 1.87)μg/(h·ml); AUC(0-inf) was(9.94 ± 2. 11)μg/(h·ml) and( 10.12 ± 1.92)μg/(h· ml) for test and reference formulations, respectively. The 90% confidential interval of AUC(0-14) of tested formulation was 94.1% - 104.3% while the 90% of that of AUC(0-inf) was 93.0 % - 102.8 %, and 95.7 % - 113.9 % for Cmax. Conclusion : The relative bioavailability of test formulation to reference formulation was (100.4 ± 17.0)%, which suggests there is bioequivalence of the two agents.
出处 《皖南医学院学报》 CAS 2007年第3期167-170,共4页 Journal of Wannan Medical College
关键词 伐昔洛韦 阿昔洛韦 药代动力学 相对生物利用度 生物等效性 高效液相色谱法 valaciclovir acyclovir pharmacokinetics relative bioavailability bioequivalence high performance liquid chromatography
  • 相关文献

参考文献5

二级参考文献30

  • 1廉江平,丰航,毛幼桦.阿昔洛韦片在健康志愿者体内的相对生物利用度[J].第四军医大学学报,2004,25(19):1802-1804. 被引量:3
  • 2陈宏,赖永旭.盐酸伐昔洛韦的临床研究综述[J].四川医学,2005,26(4):467-468. 被引量:8
  • 3蒋学华,陈小瑞,程强,胡继承,孙健.盐酸伐昔洛韦片的药动学与生物利用度[J].中国药学杂志,1997,32(2):100-103. 被引量:20
  • 4陈新谦 金有豫.新编药物学,第14版[M].人民卫生出版社,1998.532.
  • 5陈新谦,新编药物学(第14版),1998年,142页
  • 6邓树海,药物动力学理论与实践,1998年,85页
  • 7魏树礼,生物药剂学与药物动力学,1997年,10页
  • 8BANGARU RA, BANSAL YK, RAO AR, et al. Rapid, simple and sensitive high-performance liquid chromatographic method for detection and determination of acyclovir in human plasma and its use in bioavailability studies[J]. J Chromatogr B, 2000,739(2):231-237.
  • 9Chuong P H.Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution[J].J Chromat B,1999,732(1):47 -53.
  • 10Erik DC, Hugh JF. Antiviral prodrugs-the development of successful prodrug strategies for antiviral chemotherapy [J]. Br J Pharmacol,2006,147(1) :1 - 11.

共引文献35

同被引文献29

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部